The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.

MLA

Koster, Joseph C., et al. “The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood That Is Improved with Sulfonylurea Therapy.” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 3, Mar. 2008, pp. 1054–61. EBSCOhost, https://doi.org/10.1210/jc.2007-1826.

APA

Koster, J. C., Cadario, F., Peruzzi, C., Colombo, C., Nichols, C. G., & Barbetti, F. (2008). The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. The Journal of Clinical Endocrinology and Metabolism, 93(3), 1054–1061. https://doi.org/10.1210/jc.2007-1826

Chicago

Koster, Joseph C, Francesco Cadario, Cinzia Peruzzi, Carlo Colombo, Colin G Nichols, and Fabrizio Barbetti. 2008. “The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood That Is Improved with Sulfonylurea Therapy.” The Journal of Clinical Endocrinology and Metabolism 93 (3): 1054–61. doi:10.1210/jc.2007-1826.